SCHEMBL29595094

SCHEMBL29595094

C#C[C@]1(O)CC[C@H]2[C@@H]3CC=C4CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PGR P06401 8/20 0.67
▸ LMNA P02545 7/20 0.67
▸ SLC6A4 P31645 7/20 0.67
▸ CYP3A4 P08684 6/20 0.67
▸ ESR1 P03372 6/20 0.67
▸ SHBG P04278 5/20 0.67
▸ AR P10275 5/20 0.67
▸ ABCB11 O95342 4/20 0.67
▸ NR3C1 P04150 4/20 0.67
▸ CYP2C19 P33261 4/20 0.67
▸ MEN1 O00255 2/20 0.67
▸ KMT2A Q03164 2/20 0.67
▸ POLB P06746 1/20 0.67
▸ NR1I2 O75469 3/20 0.59
▸ OPRM1 P35372 3/20 0.49
▸ TSHR P16473 2/20 0.46
▸ HIF1A Q16665 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ ADRA2A P08913 1/20 0.46
▸ ADORA3 P0DMS8 3/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levonorgestrel SCHEMBL14360765 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Norgestrel SCHEMBL4319113 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Levonorgestrel SCHEMBL3916570 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Levonorgestrel SCHEMBL825664 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Levonorgestrel SCHEMBL27597 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Levonorgestrel SCHEMBL691861 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Levonorgestrel SCHEMBL22364344 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Levonorgestrel SCHEMBL21741985 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Levonorgestrel SCHEMBL20927506 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1
Norgestrel SCHEMBL37118 0.80 PGR (1.00) PGRLMNASLC6A4CYP3A4ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11766400-B2 Biodegradable contraceptive implants YALE UNIVERSITY (US) 2023-09-26 — — US claimed
US-20250248928-A1 NANOPARTICLES AND NANOPARTICLE-RELEASING VAGINAL RINGS YALE UNIVERSITY 2025-08-07 — — US disclosed
EP-4507675-A1 NANOPARTICLES AND NANOPARTICLE-RELEASING VAGINAL RINGS Yale University (US) 2025-02-19 — — EP disclosed
CN-118317794-A Composition for treating dysmenorrhea 戴尔生物科学公司 2024-07-09 — — CN disclosed
US-11814408-B2 Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof NICOX OPHTHALMICS, INC. (US) 2023-11-14 — — US disclosed
WO-2023200974-A1 NANOPARTICLES AND NANOPARTICLE-RELEASING VAGINAL RINGS YALE UNIVERSITY (US) 2023-10-19 — — WO disclosed
US-11766400-B2 Biodegradable contraceptive implants YALE UNIVERSITY (US) 2023-09-26 — — US disclosed
US-20220175872-A1 THERMOGENIC COMPOSITIONS AND METHODS OHIO STATE INNOVATION FOUNDATION 2022-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11766400-B2 Biodegradable contraceptive implants LHCGR, PGF, SHBG PGR 4/4885LMNA 399/4885SLC6A4 4788/4885
US-20220175872-A1 THERMOGENIC COMPOSITIONS AND METHODS LRBA, IAPP, FABP4 PGR 3717/4885LMNA 1305/4885SLC6A4 3581/4885
US-20250248928-A1 NANOPARTICLES AND NANOPARTICLE-RELEASING VAGINAL RINGS MUC1, CD63, EPCAM PGR 4/4885LMNA 2222/4885SLC6A4 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback